

**SENSITIZATION OF HER-2/NEU OVEREXPRESSING**  
**CANCER CELLS TO CHEMOTHERAPY**

**ABSTRACT**

The present invention relates to methods for the inhibition, of the gene product  
of the *neu* oncogene, p185*neu* tyrosine kinase. Over-expression of the *neu* oncogene  
leads to chemoresistance. The methods disclosed involve the novel use of E1A and/or  
LT in combination with chemotherapeutic drugs to treat carcinoma. Furthermore, E1A  
surprisingly potentiates the antineoplastic effects of the chemotherapeutic agents. The  
inventors propose that E1A sensitizes cancer cells such that they become amenable to  
treatment by chemotherapeutic drugs.